Cargando…

MOSAIC: A cohort study of human mpox virus disease

BACKGROUND: Human mpox is a viral disease caused by an Orthopoxvirus, human mpox virus (hMPXV), typically causing fever and a rash. Mpox has historically been endemic to parts of Central and West Africa, with small numbers of imported cases reported elsewhere, but starting May 2022 an unprecedented...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pesonel, Elise, Hoffmann, Isabelle, Guiraud, Laetitia, Bourner, Josephine, Diallo, Alpha, Dunning, Jake, Horby, Peter, Kali, Sabrina, Laouénan, Cédric, Mentré, France, Merson, Laura, Molino, Diana, Palich, Romain, Rojek, Amanda, Tacconelli, Evelina, Tardivon, Coralie, Yazdanpanah, Yazdan, Calmy, Alexandra, Lescure, F-Xavier, Olliaro, Piero
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	F1000 Research Limited 2023
Materias:	Study Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10685065/ https://www.ncbi.nlm.nih.gov/pubmed/38031544 http://dx.doi.org/10.12688/wellcomeopenres.19616.2

Ejemplares similares

Randomised controlled trials for mpox in endemic countries
por: Rojek, Amanda, et al.
Publicado: (2023)

Type 1 interferons as a potential treatment against COVID-19
por: Sallard, Erwan, et al.
Publicado: (2020)

Corrigendum to “Review of trials currently testing treatment and prevention of COVID-19” [Clin Microbiol Infect 26.8 (2020) 988–998]
por: Fragkou, Paraskevi C., et al.
Publicado: (2021)

Laboratory Diagnosis of Mpox, Central African Republic, 2016–2022
por: Garba-Ouangole, Sandra, et al.
Publicado: (2023)

Tecovirimat for Monkeypox in the Central African Republic under Expanded Access
por: Mbrenga, Festus, et al.
Publicado: (2022)

Clinical trial simulation to evaluate power to compare the antiviral effectiveness of two hepatitis C protease inhibitors using nonlinear mixed effect models: a viral kinetic approach
por: Laouénan, Cédric, et al.
Publicado: (2013)

Evaluation by simulation of clinical trial designs for evaluation of treatment during a viral haemorrhagic fever outbreak
por: Manchon, Pauline, et al.
Publicado: (2021)

Monkeypox: how will we know if the treatments work?
por: Rojek, Amanda, et al.
Publicado: (2022)

Accelerating clinical trial implementation in the context of the COVID-19 pandemic: author's response
por: Trøseid, Marius, et al.
Publicado: (2022)

A Case of Mpox Reinfection
por: Musumeci, Stefano, et al.
Publicado: (2023)

Clinical characterization of Lassa fever: A systematic review of clinical reports and research to inform clinical trial design
por: Merson, Laura, et al.
Publicado: (2021)

Evaluation of model‐based bioequivalence approach for single sample pharmacokinetic studies
por: Tardivon, Coralie, et al.
Publicado: (2023)

Regulatory and Operational Complexities of Conducting a Clinical Treatment Trial During an Ebola Virus Disease Epidemic
por: Rojek, Amanda M, et al.
Publicado: (2018)

Review of trials currently testing treatment and prevention of COVID-19
por: Fragkou, P.C., et al.
Publicado: (2020)

Modeling SARS-CoV-2 viral kinetics and association with mortality in hospitalized patients from the French COVID cohort
por: Néant, Nadège, et al.
Publicado: (2021)

A monoclonal antibody stands out against omicron subvariants: a call to action for a wider access to bebtelovimab
por: Hentzien, Maxime, et al.
Publicado: (2022)

Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial
por: Ader, Florence, et al.
Publicado: (2022)

The number of cases, mortality and treatments of viral hemorrhagic fevers: A systematic review
por: Belhadi, Drifa, et al.
Publicado: (2022)

COVID-19 : les thérapeutiques
por: KHERABI, Yousra, et al.
Publicado: (2022)

Management of pharmacovigilance during the COVID‐19 pandemic crisis by the safety department of an academic sponsor: Lessons learnt and challenges from the EU DisCoVeRy clinical trial
por: Mercier, Noémie, et al.
Publicado: (2023)

Ten months of temporal variation in the clinical journey of hospitalised patients with COVID-19: An observational cohort
por: Hall, Matthew D, et al.
Publicado: (2021)

No increased prevalence of autoantibodies neutralizing type I IFNs in idiopathic pulmonary fibrosis patients
por: Philippot, Quentin, et al.
Publicado: (2023)

Clinical REsearch During Outbreaks (CREDO) Training for Low- and Middle-Income Countries
por: Kayem, Nzelle Delphine, et al.
Publicado: (2019)

Persistent COVID-19 symptoms are highly prevalent 6 months after hospitalization: results from a large prospective cohort
por: Ghosn, Jade, et al.
Publicado: (2021)

Different Factors Associated with CTX-M-Producing ST131 and Non-ST131 Escherichia coli Clinical Isolates
por: Nicolas-Chanoine, Marie-Hélène, et al.
Publicado: (2013)

Low serum neutralization of Omicron variants a month after AZD7442 prophylaxis initiation
por: de Lamballerie, Xavier, et al.
Publicado: (2023)

Severe SARS-CoV-2 infections: practical considerations and management strategy for intensivists
por: Bouadma, Lila, et al.
Publicado: (2020)

Patient-centered approach to the management of drug-resistant tuberculosis in France: How far off the mark are we?
por: Kherabi, Yousra, et al.
Publicado: (2022)

Pilot Phase II study of mazindol in children with attention deficit/hyperactivity disorder
por: Konofal, Eric, et al.
Publicado: (2014)

Accelerating clinical trial implementation in the context of the COVID-19 pandemic: challenges, lessons learned and recommendations from DisCoVeRy and the EU-SolidAct EU response group
por: Diallo, Alpha, et al.
Publicado: (2022)

Mpox-associated myopericarditis
por: Al-Tawfiq, Jaffar A., et al.
Publicado: (2023)

Viroporins of Mpox Virus
por: Basu, Kingshuk, et al.
Publicado: (2023)

Prescription des bloqueurs du SRAA avant et après l’admission chez les patients hospitalisés pour COVID-19, et association avec la mortalité. Implications pour l’interprétation des études observationnelles sur le rôle des bloqueurs du SRAA durant l’infection à SARS-CoV-2
por: Lahens, A., et al.
Publicado: (2020)

Complement-dependent mpox-virus-neutralizing antibodies in infected and vaccinated individuals
por: Hubert, Mathieu, et al.
Publicado: (2023)

Symptom‐based case definitions for COVID‐19: Time and geographical variations for detection at hospital admission among 260,000 patients
por: Baruch, Joaquin, et al.
Publicado: (2022)

A systematic review of the clinical profile of patients with bubonic plague and the outcome measures used in research settings
por: Bourner, Josephine, et al.
Publicado: (2023)

2674. Disparities in Mpox Care: Use of the Social Vulnerability Index to Predict Mpox Infections
por: Leonard, Michael, et al.
Publicado: (2023)

Which breast cancer decisions remain non-compliant with guidelines despite the use of computerised decision support?
por: Séroussi, B, et al.
Publicado: (2013)

High doses of favipiravir in two men survivors of Ebola virus disease carrying Ebola virus in semen in Guinea
por: Eloy, Philippine, et al.
Publicado: (2022)

Recent advances on human mpox
por: Orassay, Aliya, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_pv9b2k8r019rehhinfq262a6p4